Celcuity Inc.: Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma Biotechnology
Celcuity Inc.: Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma Biotechnology - UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate - Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HER2-negative breast cancer patients selected by the CELsignia® Test MINNEAPOLIS, MN / ACCESSWIRE / December 23, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company utilizing its 3 rd generation companion diagnostics to identify new targeted therapeut...
Source: finanznachrichten.de